Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Clinical trial NCT05453396 · TERMINATED

Trial details

NCT number: NCT05453396
Sponsor: University of Washington
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Mantle Cell Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Mantle Cell Lymphoma

Start date: 2023-08-07
Primary completion: 2026-05-05
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.